Preclinical studies showed that SGN-CD123A demonstrated anti-tumor activity against AML cell lines and primary samples from AML patients with or without adverse cytogenetic profiles or FLT3 mutations [116]. Here, FLT3 is linked to acute myeloid leukemia.